Plain-English translation of NCT07523620 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial evaluates whether using two devices together in a single procedure is safe and works well for people with atrial fibrillation (a common irregular heartbeat). The first device, called the Volt Pulsed Field Ablation System, treats the irregular heartbeat by using energy to correct the heart's rhythm. The second device, the Amulet 2 Left Atrial Appendage Occluder, is a small implant that seals off a pouch in the heart to prevent blood clots.
Many people with atrial fibrillation need both rhythm correction and blood clot prevention, but these have traditionally required separate procedures or prolonged medication use. This trial tests whether doing both treatments at once—in a single procedure—is safer, easier, and more effective for patients.
You likely qualify if…
You likely don't qualify if…
You would undergo a single procedure where doctors use both the new ablation device and the occluder device to treat your atrial fibrillation and prevent blood clots. After the procedure, you would take blood-thinning medication for at least 60 days, followed by aspirin or a similar medication for ongoing heart health. You would need to attend follow-up visits so doctors can monitor your heart rhythm and ensure both devices are working safely.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
Belgium
Czechia
Denmark
Germany